(Q35760264)

10 August 2017

1 reference

title

Prevention of hepatitis C virus infection (English)

1 reference

10 August 2017

1 reference

M Kew

1

1 reference

10 August 2017

G François

2

1 reference

10 August 2017

D Lavanchy

3

1 reference

10 August 2017

H Margolis

4

1 reference

10 August 2017

P Van Damme

5

1 reference

10 August 2017

P Grob

6

1 reference

10 August 2017

J Hallauer

7

1 reference

10 August 2017

D Shouval

8

1 reference

10 August 2017

G Leroux-Roels

9

1 reference

10 August 2017

A Meheus

10

1 reference

10 August 2017

Viral Hepatitis Prevention Board

11

1 reference

10 August 2017

1 May 2004

1 reference

Journal of Viral Hepatitis

10 August 2017

1 reference

10 August 2017

11

1 reference

10 August 2017

3

1 reference

10 August 2017

198-205

1 reference

Epidemiology of hepatitis C: geographic differences and temporal trends

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Is severe liver disease a common outcome for people with chronic hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Polyethylene glycol-interferon: current status in hepatitis C virus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

HCV genotypes--role in pathogenesis of disease and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

Hepatitis C in hospital employees with needlestick injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00492.X

10.1111/J.1365-2893.2004.00492.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference